Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $51.75.
Several equities research analysts recently weighed in on the stock. Weiss Ratings began coverage on shares of Scribe Therapeutics in a report on Tuesday, October 20th. They issued a “sell (e-)” rating for the company. Wall Street Zen raised shares of Scribe Therapeutics to a “hold” rating in a research note on Saturday, August 1st. Guggenheim initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price target for the company. Finally, HC Wainwright started coverage on shares of Scribe Therapeutics in a research note on Monday, August 31st. They issued a “buy” rating and a $60.00 price target for the company.
Get Our Latest Stock Analysis on SCTX
Institutional Investors Weigh In On Scribe Therapeutics
A hedge fund recently bought a new stake in Scribe Therapeutics stock. Goldman Sachs Group Inc. purchased a new stake in shares of Scribe Therapeutics Inc. (NASDAQ:SCTX – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 21,635 shares of the company’s stock, valued at approximately $398,000. Goldman Sachs Group Inc. owned approximately 0.11% of Scribe Therapeutics as of its most recent filing with the SEC.
Scribe Therapeutics Price Performance
Shares of SCTX opened at $15.37 on Tuesday. The company has a market capitalization of $290.95 million and a PE ratio of -1.41. The stock’s fifty day moving average price is $20.86. Scribe Therapeutics has a 12-month low of $13.50 and a 12-month high of $39.60.
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.64 million during the quarter. Sell-side analysts predict that Scribe Therapeutics will post -3.68 EPS for the current year.
About Scribe Therapeutics
Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.
See Also
- Five stocks we like better than Scribe Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
